Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review
Idiopathic pulmonary fibrosis (IPF) is an incurable, debilitating disease which impairs lung function and eventually leads to death. Currently, there is a lack of effective modifying therapies and treatments for IPF as the underlying epidemiological mechanism is not clearly understood. This leads to difficulty in diagnosing and managing IPF, which results in a high incurment of disease-associated cost. Even though IPF poses a substantial economic burden, there is a lack of research available on cost triggers and healthcare utilization, which can be a barrier to future economic evaluations of new medicines for IPF.
We aimed to conduct a systematic literature review (SLR) to identify the key cost-generating events of IPF and to gather any related costing information.
The data showed that the main events triggering high resource use in patients were the symptoms of IPF progression along with comorbidities and lung transplantations. These events result in a high economic impact through the use of medications, health care professionals, and hospital stays.
More research is needed to identify the direct, and indirect, relationships between IPF events and the costs they generate. This would help to further evaluate the area of need for future health technologies and to understand what events should be targeted to reduce the global economic burden of IPF.
KeywordsIdiopathic pulmonary fibrosis Cost Economic impact Systematic review Cost triggers Financial burden
- 1.Loveman E, Copley VR, Colquitt J, Scott DA, Clegg A, Jones J, O’Reilly KM, Singh S, Bausewein C, Wells A (2015) The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. Health Technol Assess 19:1–336 i–xxivCrossRefPubMedPubMedCentralGoogle Scholar
- 4.Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRefPubMedGoogle Scholar
- 8.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Johnston K, Buxton M, Jones D, Fitzpatrick R (1999) Assessing the costs of healthcare technologies in clinical trials. Health Technol Assess, vol. 3Google Scholar
- 11.Statistics, B.o.L. (2015) Consumer price index-all urban consumersGoogle Scholar
- 13.NICE (2013) Idiopathic pulmonary fibrosis costing report. National Institute for Health and Care Excellence, ManchesterGoogle Scholar
- 14.Loveman E, Copley VR, Colquitt JL, Scott DA, Clegg AJ, Jones J, O’Reilly KM, Singh S, Bausewein C, Wells A (2014) The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol 15:63CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Chen S-Y, Collard HR, Yeh W-S, Li Q, Lee Y-C, Wang A, Raghu G, International B Francisco U.o.C.S. and Evidera (2014) An analysis of US medicare beneficiaries: Burden of direct medical costs in patients with idiopathic pulmonary fibrosis. In: ISPOR 17th Annual European Congress, Amsterdam, The NetherlandsGoogle Scholar
- 25.Excellence, N.I.f.H.a.C. (2015) Nintedanib for treating idiopathic pulmonary fibrosis NICEGoogle Scholar
- 26.Eliot O-T, Yanxin W, Bonni H, Hongwei W, Juliette M (2012) the economic burden of idiopathic pulmonary fibrosis from diagnosis to lung transplant. In: A40, the economic burden of respiratory disease and cost-effectiveness of treatments, American Thoracic Society, pp A1497–A1497Google Scholar
- 29.Excellence N.I.f.H.a.C (2013) Pirfenidone for treating idiopathic pulmonary fibrosis. In: Final appraisal determination, NICEGoogle Scholar
- 30.Ferreira LM (2014) Two new IPF treatments will reportedly will cost between $94 K and $96 K a yearGoogle Scholar